Assess whether pediatric studies are necessary or waivable (6cf587)

Situation

The desk packet is CMC comparability package for a site change after a CRL citing manufacturing, not efficacy. RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences Pharmacovigilance file.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Pediatric studies are necessary / Waivable using CMC comparability package for a site change after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• CMC comparability package for a site change reads as Pediatric studies are necessary once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population.
• CMC comparability package for a site change is closer to Waivable after a CRL citing manufacturing, not efficacy; Pediatric studies are necessary would over-claim this Pharmacovigilance extract.
• A dual reading is still live in CMC comparability package for a site change for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT.
• CMC comparability package for a site change is missing the fact RWE evidence-strategy director needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether CMC comparability package for a site change supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a CRL citing manufacturing, not efficacy and write the one fact that would move pediatric studies are necessary for RWE evidence-strategy director.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a CRL citing manufacturing, not efficacy). The follow-on Pharmacovigilance action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.